Printer Friendly

Aratana Therapeutics files for FDA approval of NOCITA for extended pain control in dogs.

M2 EQUITYBITES-July 1, 2016-Aratana Therapeutics files for FDA approval of NOCITA for extended pain control in dogs

(C)2016 M2 COMMUNICATIONS http://www.m2.com

Pet therapeutics company Aratana Therapeutics (NasdaqGM:PETX) reported on Thursday the submission of an administrative New Animal Drug Application (NADA) for NOCITA with the US Food and Drug Administration's Center for Veterinary Medicine (CVM), for cranial cruciate ligament surgery in dogs.

The Animal Drug User Fee Act (ADUFA) date for approval is 28 August 2016 and the company anticipates NOCITA will be commercially launched to veterinarians in the fall of 2016.

According to the company, NOCITA (bupivacaine liposome injectable suspension) is a local post-operative analgesia for cranial cruciate ligament surgery in dogs.

NOCITA is a long-acting, local anesthetic that lasts up to 72 hours post-surgery by releasing bupivacaine over time from multi-vesicular liposomes deposited in the tissue. The therapeutic is administered as a single dose by tissue infiltration during closure of cranial cruciate ligament surgery in dogs.

((Comments on this story may be sent to info@m2.com))

COPYRIGHT 2016 Normans Media Ltd.
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2016 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:M2 EquityBites (EQB)
Date:Jul 1, 2016
Words:173
Previous Article:Array BioPharma submits first NDA for binimetinib for treating melanoma.
Next Article:GeoVax files IND application for development and testing of preventive HIV/AIDS vaccine.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters